About EYLEA Results of phase 3 trials are presented for EYLEA.1 See the data
Proven Results Across All Approved Indications
EYLEA indications are backed by 8 pivotal studies evaluating clinical outcomes in over 3000 patients: VIEW 1 and VIEW 2 (Wet AMD) at 52 and 96 weeks, VISTA and VIVID (DME and DR in patients with DME) at 52 and 100 weeks, PANORAMA (DR) at 24 and 52 weeks, GALILEO and COPERNICUS (MEfCRVO) at 24 weeks, and VIBRANT (MEfBRVO) at 24 weeks.1 When starting a patient on EYLEA, consider the body of evidence demonstrating proven results.
Accessing EYLEA Comprehensive support for you and your patients. Find support
- AMD = Age-related Macular Degeneration
- MEfRVO = Macular Edema following Retinal Vein Occlusion (includes Branch Retinal Vein Occlusion [BRVO] and Central Retinal Vein Occlusion [CRVO])
- DME = Diabetic Macular Edema
- DR = Diabetic Retinopathy